Journal of diabetes and its complications最新文献

{"title":"Uric acid in diabetic microvascular complications: Mechanisms and therapy","authors":"Xin Li,&nbsp;Bo Huang,&nbsp;Yue Liu,&nbsp;Meng Wang,&nbsp;Jing-Qiu Cui","doi":"10.1016/j.jdiacomp.2024.108929","DOIUrl":"10.1016/j.jdiacomp.2024.108929","url":null,"abstract":"<div><div>Uric acid (UA) is mainly synthesized in the liver, intestine, and vascular endothelium and excreted by the kidney (70 %) and intestine (30 %). Hyperuricemia (HUA) occurs when UA production exceeds excretion. Many studies have found that elevated UA is associated with diabetic microvascular complications (DMC), including diabetic retinopathy (DR), diabetic nephropathy (DN), and diabetic peripheral neuropathy (DPN). In addition, too high or too low UA levels will promote the occurrence and development of chronic diseases, but the relationship between UA and diabetic microvascular complications (DMC) is not clear. Therefore, the rational treatment of UA in patients with diabetes is essential. In this review, we summarize and discuss the mechanism and treatment of UA and DMC and may provide potential advice for rational drug selection.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 2","pages":"Article 108929"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of three diagnostic glycemic measures with all-cause and cardiovascular mortality in people not on antidiabetic medications: A prospective cohort study","authors":"Jiayue Zhang ,&nbsp;Wenxiao Zheng ,&nbsp;Shuting Wang ,&nbsp;Xiangyang Gao ,&nbsp;Ying Xiao ,&nbsp;Zuyao Yang","doi":"10.1016/j.jdiacomp.2025.108970","DOIUrl":"10.1016/j.jdiacomp.2025.108970","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to investigate the value of three diagnostic glycemic measures, i.e., 2-hour plasma glucose (2hPG) during 75-g oral glucose tolerance test, fasting plasma glucose (FPG), and glycated hemoglobin (HbA1c), in predicting risk of all-cause and cardiovascular mortality after adjusting for the influence of these glycemic measures on each other.</div></div><div><h3>Methods</h3><div>A total of 14,013 U.S. adults who were not on antidiabetic medications when recruited were identified from the Third National Health and Nutrition Examination Survey (NHANES III) and NHANES 2005–2016. High blood glucose was defined as 2hPG ≥11.1 mmol/L, FPG ≥7.0 mmol/L, or HbA1c ≥6.5 %, according to the American Diabetes Association 2023 standards. Two approaches were adopted to examine the value of each glycemic measure in predicting mortality risk while controlling the influence of the other two measures: (1) adjusting for 2hPG, HbA1c, and FPG in the same model, and (2) comparing individuals showing isolated elevation of 2hPG, HbA1c, or FPG with those being “normal” for all the three measures. Major non-glycemic risk factors were adjusted for in the multivariable regression analyses.</div></div><div><h3>Results</h3><div>During a median follow-up of 9.8 years, 2869 participants died, and 960 of the deaths were attributed to cardiovascular causes. When included in the model individually, elevated 2hPG, FPG, and HbA1c were all predictive of both all-cause and cardiovascular mortality (adjusted hazard ratios ranging from 1.32 to 1.55, all <em>p</em> values &lt;0.05). After controlling the influence of the other two glycemic measures, elevated 2hPG was still statistically significantly associated with the outcomes (adjusted hazard ratios ranging from 1.04 to 1.33, depending on analytical approaches), whereas elevated FPG was not, and HbA1c was associated with cardiovascular mortality only when treated as a continuous variable and when 2hPG and FPG levels were in the normal range (adjusted hazard ratio 1.27 [1.04–1.55] for 1 % increase in HbA1c).</div></div><div><h3>Conclusions</h3><div>2hPG, FPG, and HbA1c were all predictive of all-cause and cardiovascular mortality when used alone, but when combined only 2hPG retained its predictive value for both outcomes while HbA1c predicted cardiovascular mortality only when used as a continuous variable and when 2hPG and FPG were in the normal range.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 3","pages":"Article 108970"},"PeriodicalIF":2.9,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143098442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucagon-like Peptide-1 receptor agonists versus dipeptidyl-peptidase 4 inhibitors in advanced chronic kidney disease and end stage kidney disease: Real world effectiveness and persistence of therapy","authors":"F.N.U. Sidra ,&nbsp;Shubham Agarwal ,&nbsp;Paola Lockhart Pastor ,&nbsp;Donglu Xie ,&nbsp;Xilong Li ,&nbsp;Ildiko Lingvay","doi":"10.1016/j.jdiacomp.2024.108925","DOIUrl":"10.1016/j.jdiacomp.2024.108925","url":null,"abstract":"<div><h3>Background</h3><div>Atherosclerotic cardiovascular disease is the leading cause of death in people with type 2 diabetes (T2D) and chronic kidney disease (CKD) or end-stage kidney disease (ESKD). Glucagon-Like Peptide-1 receptor agonists (GLP-1RA) reduce cardiovascular events, improve glycemic control, promote weight loss, and slow progression of nephropathy. Despite these benefits and professional society treatment guidelines recommendations, GLP-1RAs remain under-utilized in people with advanced CKD and ESKD due to tolerability and safety concerns.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study comparing clinical outcomes and medication use details after initiating GLP-1RA or dipeptidyl-peptidase 4 inhibitor (DPP-4i) in people with T2D and advanced CKD or ESKD. Eligible patients were identified via electronic health record query with extraction of baseline demographics, vital signs, and laboratory values. A manual chart review was undertaken to confirm eligibility, medication use, and extract a detailed account of all side effects.</div></div><div><h3>Results</h3><div>A total of 236 eligible patients (149 in the GLP-1RA group and 87 in the DPP-4i group) were identified. The average duration of treatment was 1036 (±909.9) and 1109 (±1090.9) days for GLP-1RA and DPP-4i, respectively. The average percentage weight loss from baseline to 36 months of treatment in the GLP-1RA group was −9.6 % (95 % CI, −11.3 to −7.8) versus −2.4 % (95 % CI, −5.4 to 0.5) in the DPP-4i group (estimated treatment difference (ETD) -7.1 (95 % CI, −10.6 to −3.7) percentage-points, <em>p</em> &lt; 0.001). The change in HbA1c from baseline to 36 months of treatment was significantly greater in the GLP-1RA (−1.0 %) compared with the DPP-4i group (0.2 %) (ETD -1.2 (95 % CI, −2.1 to −0.3) percentage-points, <em>p</em> = 0.04).</div></div><div><h3>Conclusion</h3><div>In patients with T2D and advanced CKD or ESKD, treatment with GLP-1RAs in a real-world setting had long treatment persistence, and compared to DPP-4is, was associated with greater weight loss and glycemic improvement.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108925"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of visit-to-visit glycated hemoglobin variability on diabetes distress and its subscales","authors":"So-hyeon Hong ,&nbsp;Yongho Jee ,&nbsp;Yeon-Ah Sung ,&nbsp;Young Sun Hong ,&nbsp;Do Kyeong Song ,&nbsp;Hyein Jung ,&nbsp;Hyejin Lee","doi":"10.1016/j.jdiacomp.2024.108924","DOIUrl":"10.1016/j.jdiacomp.2024.108924","url":null,"abstract":"<div><h3>Aims</h3><div>This study aimed to investigate the correlations between glycated hemoglobin (HbA1C) variability and diabetes distress (DD) and its subscales in older patients with type 2 diabetes mellitus.</div></div><div><h3>Methods</h3><div>The cross-sectional study analyzed 175 patients with type 2 diabetes mellitus, aged ≥60 years, and underwent HbA1C testing at least three times within a 2-year. HbA1C variability was assessed using the coefficient of variation (CV), standard deviation (SD), variability independent of the mean (VIM), and variability score. DD was assessed using a diabetes distress scale (DDS) questionnaire. We analyzed four DDS subscales, including emotional burden (EB), regimen distress (RD), interpersonal distress (ID), and physician distress (PD). Significant DD was defined as a total score ≥ 34.</div></div><div><h3>Results</h3><div>All four indices of HbA1C variability were positively correlated with DDS (<em>r</em> = 0.19, <em>P</em> = 0.01 in CV; <em>r</em> = 0.19, <em>P</em> = 0.01 in SD; <em>r</em> = 0.19, <em>P</em> = 0.02 in VIM; and <em>r</em> = 0.18, <em>P</em> = 0.02 in variability score). For the DD subscales, only EB showed a significant correlation with HbA1C variability (<em>β</em> = 0.72, SE = 0.35 in CV; <em>β</em> = 0.70, SE = 0.35 in SD; <em>β</em> = 0.66, SE = 0.31 in VIM; and <em>β</em> = 0.77, SE = 0.35 in variability score).</div></div><div><h3>Conclusions</h3><div>HbA1C variability was independently linked to DD, particularly the EB subscale in older type 2 diabetes patients. This underscores the need for DD screening and intervention in patients with high HbA1C variability, irrespective of their HbA1C levels or depressive symptoms.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108924"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cambridge risk score, new hyperglycemia, and complications in surgical patients without diabetes","authors":"Hannah Lee ,&nbsp;Phillip J. Hartfield ,&nbsp;Abigail Thorgerson ,&nbsp;Grant P. Sinson ,&nbsp;Marjorie Wang ,&nbsp;Carlos E. Mendez","doi":"10.1016/j.jdiacomp.2024.108926","DOIUrl":"10.1016/j.jdiacomp.2024.108926","url":null,"abstract":"<div><h3>Aims</h3><div>Our study examined the association between the Cambridge Risk Score (CRS), new hyperglycemia (NH), and complications in patients undergoing elective surgery.</div></div><div><h3>Methods</h3><div>In this retrospective cross-sectional study, adult surgical patients, without diabetes, with NH (blood glucose ≥140 mg/dL) were identified, and the CRS was calculated. We used univariate regression models to evaluate the relationship between CRS and NH with 30-day readmission, length of stay (LOS), and complications. Models were stratified by surgical specialty (cardiac/vascular, general, orthopedic, neurologic).</div></div><div><h3>Results</h3><div>Of 10,531 patients in the study, 24 % had NH. After adjusting for covariates, the CRS was associated with increased odds of complications [OR 2.09; 95%CI:1.69, 2.59] and NH [OR 1.95; 95%CI:1.66, 2.29]. NH was associated with increased odds of 30-day readmission [β 1.60; 95%CI:1.31, 1.96], and increased LOS [β 0.64; 95%CI:0.59, 0.68]. When stratified by surgery type, the CRS was associated with increased LOS in neurosurgery, decreased LOS in orthopedics, and increased odds of complications and NH in neurosurgery and orthopedics.</div></div><div><h3>Conclusion</h3><div>The CRS is associated with NH, complications, and LOS in patients undergoing elective neurosurgery, orthopedic surgery, and general surgery. This suggests that CRS may have potential to help identify surgical patients at high risk for NH and complications.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108926"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents/Barcode","authors":"","doi":"10.1016/S1056-8727(24)00263-0","DOIUrl":"10.1016/S1056-8727(24)00263-0","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108937"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143155084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic effects of GLP-1 mimetics in diabetic milieu: A mechanistic review of involved pathways","authors":"Habib Yaribeygi ,&nbsp;Kiana Kashian ,&nbsp;Kimia Imani Moghaddam ,&nbsp;Sheida Rashmeh Karim ,&nbsp;Narges Bagheri ,&nbsp;Sercan Karav ,&nbsp;Tannaz Jamialahmadi ,&nbsp;Manfredi Rizzo ,&nbsp;Amirhossein Sahebkar","doi":"10.1016/j.jdiacomp.2024.108928","DOIUrl":"10.1016/j.jdiacomp.2024.108928","url":null,"abstract":"<div><div>Patients with diabetic are at a higher risk of developing hepatic disorders compared to non-diabetic individuals. This increased risk can be attributed to the diabetic environment, which triggers and exacerbates harmful pathways involved in both diabetic complications and hepatic disorders. Therefore, it is important to consider the use of antidiabetic agents that offer benefits beyond glycemic control and have positive effects on liver tissues. Glucagon-like peptide-1 (GLP-1) mimetics are a novel class of antidiabetic medications known for their potent blood sugar-lowering effects. Emerging evidence suggests that these drugs also have favorable effects on the liver. However, the precise effects and underlying mechanisms are not yet fully understood. In this review, we aim to provide a mechanistic perspective on the liver benefits of GLP-1 mimetics and outline the mediating mechanisms involved.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108928"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Slowly progressive subtype of childhood-onset type 1 diabetes as a high-risk factor for end-stage renal disease: A cohort study in Japan","authors":"Hiroshi Yokomichi ,&nbsp;Mie Mochizuki ,&nbsp;Shigeru Suzuki ,&nbsp;Yoshiya Ito ,&nbsp;Tomoyuki Hotsubo ,&nbsp;Nobuo Matsuura","doi":"10.1016/j.jdiacomp.2024.108922","DOIUrl":"10.1016/j.jdiacomp.2024.108922","url":null,"abstract":"<div><h3>Aim</h3><div>To compare the incidence of end-stage renal disease (ESRD) between slowly progressive type 1 diabetes and acute-onset type 1 diabetes.</div></div><div><h3>Methods</h3><div>This cohort study enrolled all 521 patients with childhood-onset type 1 diabetes with the year of onset from 1959 to 1996 in Hokkaido Prefecture, Japan. We calculated the ESRD incidence rate per 100,000 person-years by sex, onset year, onset age, and type 1 diabetes subtype (slowly progressive or acute-onset). We also constructed a Kaplan–Meier curve for ESRD by these risk factors.</div></div><div><h3>Results</h3><div>The data of 391 patients were gathered, among whom 66 developed ESRD. The ESRD incidence rate per 100,000 person-years was 525 among all patients; 538 and 503 among women (<em>n</em> = 235) and men (<em>n</em> = 156); 893, 413, and 225 for onset year of 1959–1979 (<em>n</em> = 107), 1980–1989 (<em>n</em> = 201), and 1990–1996 (<em>n</em> = 83); 420 and 715 for onset before (<em>n</em> = 243) and after (<em>n</em> = 148) puberty; and 1388 and 432 for the slowly progressive (<em>n</em> = 41) and acute-onset (<em>n</em> = 350) subtypes, respectively. The Kaplan–Meier curve also indicated a significantly higher incidence of ESRD in slowly progressive than in acute-onset type 1 diabetes.</div></div><div><h3>Conclusion</h3><div>The incidence of ESRD was higher in slowly progressive than acute-onset type 1 diabetes.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108922"},"PeriodicalIF":2.9,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142747984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic importance of baseline and changes in serum uric acid for macro/microvascular and mortality outcomes in individuals with type 2 diabetes: The Rio de Janeiro type 2 diabetes cohort","authors":"Claudia R.L. Cardoso,&nbsp;Lucas da Silva Pereira,&nbsp;Nathalie C. Leite,&nbsp;Gil F. Salles","doi":"10.1016/j.jdiacomp.2024.108921","DOIUrl":"10.1016/j.jdiacomp.2024.108921","url":null,"abstract":"<div><h3>Aims</h3><div>To investigate the associations between baseline/changes in serum uric acid (sUA) and the risks for cardiovascular/microvascular outcomes and mortality in a type 2 diabetes cohort.</div></div><div><h3>Methods</h3><div>Baseline sUA was measured in 685 individuals, and 463 had a second sUA measurement during follow-up; sUA was analyzed as a continuous variable and categorized into sex-specific tertile subgroups and low/high levels (&gt;4.5 mg/dl women; &gt;5.5 mg/dl men). The risks associated with baseline sUA and its changes were examined by Cox analyses for all outcomes.</div></div><div><h3>Results</h3><div>Median follow up was 10.7 years, there were 173 major cardiovascular events (MACEs), 268 all-cause deaths, 127 microalbuminuria, 104 renal failure, 160 retinopathy and 178 peripheral neuropathy outcomes. Baseline sUA was predictor of all outcomes, except all-cause mortality and retinopathy. In tertile and high/low sUA analyses, the hazard ratios (HRs) varied from 1.6 (microalbuminuria development) to 2.4 (MACEs; cardiovascular mortality). There was interaction with sex for MACEs, an increased risk was observed in women (HR: 2.6), but not in men (HR: 1.2). Changes in sUA were associated with the renal failure (HR: 2.4).</div></div><div><h3>Conclusions</h3><div>In a prospective cohort, high baseline sUA was a predictor of cardiovascular, renal and peripheral neuropathy. However, sUA changes were only predictor of renal failure.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108921"},"PeriodicalIF":2.9,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142747985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents/Barcode","authors":"","doi":"10.1016/S1056-8727(24)00242-3","DOIUrl":"10.1016/S1056-8727(24)00242-3","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"38 12","pages":"Article 108916"},"PeriodicalIF":2.9,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142703515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}